###### Strengths and limitations of this study

-   The Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) study is the largest randomised clinical trial ever conducted among patients with bloodstream infection and should set the paradigm for antibiotic treatment duration for these patients.

-   BALANCE will provide generalisable results by including a wide array of bloodstream pathogens and underlying sources of infection, examining both critically and non-critically ill hospitalised patients, and including sites across six countries with varying baseline antibiotic resistance rates.

-   If 7 days of antibiotic treatment is non-inferior to 14 days of treatment, this could lead to reductions in global antibiotic use, costs and antibiotic-related complications, including adverse events, *Clostridium difficile* and antibiotic resistance.

-   The diversity of pathogens and underlying infections that cause bloodstream infection render placebo controls infeasible. We will minimise bias through central randomisation, allocation concealment until day 7, an objective primary outcome and blinded adjudication of other outcomes such as relapse and secondary infections with antibiotic-resistant organisms.

Introduction {#s1}
============

There are more than 600 000 episodes of bloodstream infection per year in North America, and more than 1 200 000 episodes in Europe.[@R1] These infections affect 15% of critically ill patients, result in prolongation of hospital stay, excess healthcare costs and a substantial mortality.[@R2]

Hospitals, and intensive care units (ICUs) in particular, are the location of greatest antimicrobial pressure; however, audits indicate that 30%--50% of antibiotic use in acute care and critical care settings are unnecessary or inappropriate[@R6] and leads to avoidable costs and complications. Antibiotics are among the most common cause of serious adverse drug events,[@R9] which occur in up to 5%--10% of inpatient recipients.[@R10] Excessive durations of antibiotic therapy are the largest contributor to inappropriate antibiotic use in acute care hospitals, long-term care facilities and ambulatory clinics.[@R7] Discontinuing antibiotics after achieving clinical cure can potentially reduce the burden of adverse events, *Clostridium difficile* infections and selection of antibiotic-resistant pathogens.[@R14]

Meta-analysis of randomised clinical trials (RCTs) has demonstrated that shorter duration antibiotic treatment is as effective as longer duration treatment for a range of mild to moderate infections.[@R16] Even in critically ill patients with ventilator-associated pneumonia, mortality rates and relapse rates were non-inferior among the 402 patients randomised to receive shorter (8 day) versus longer (15 day) courses of antibiotics.[@R17] However, similar high-grade evidence is lacking for the treatment of critically ill patients with bloodstream infections.[@R2] One recent study has examined 7 versus 14 days of treatment for bacteraemia in non-critically ill patients and has suggested that this may be a safe approach, but used a wide non-inferiority margin and was limited to infections with Gram-negative pathogens.[@R20] Specific guidelines for treatment durations exist for pneumonia,[@R22] intra-abdominal infection,[@R24] catheter-related bloodstream infection,[@R25] pyelonephritis[@R26] and skin and soft tissue infection[@R27] but no guidelines exist for the optimal duration of treatment for the subset of patients with bacteraemia.

We have performed a systematic review of the existing literature,[@R19] practice surveys of infectious diseases and critical care physicians,[@R28] a single-centre[@R30] and multicentre observational study,[@R31] which collectively identified gaps in current evidence, extensive practice variation and equipoise for a randomised trial comparing shorter (7 days) versus longer (14 days) antibiotic treatment durations for bloodstream infections. Through the Bacteremia Antibiotic Length Actually Needed For Clinical Effectiveness (BALANCE) pilot RCT (ClinicalTrials.gov identifier: NCT02261506), we documented the feasibility of this trial design among 115 patients in ICUs, thereby providing a vanguard for the BALANCE main trial.[@R32] We have subsequently confirmed the feasibility of enrolling patients on non-ICU wards in a parallel pilot RCT (ClinicalTrials.gov identifier NCT02917551), facilitating expansion of the BALANCE trial to include non-ICU patients.[@R33]

The primary aim of the BALANCE RCT will be to determine whether 7 days (as compared with 14 days) of adequate antibiotic treatment is associated with non-inferior 90-day survival for hospitalised patients with bacteraemia.

Methods and analysis {#s2}
====================

Study design {#s2-1}
------------

We will conduct a multicentre randomised concealed allocation trial of shorter duration (7 days) versus longer duration (14 days) antibiotic treatment for patients with bacteraemia admitted to hospital.

Setting {#s2-2}
-------

The BALANCE trial (balance.ccctg.ca) is currently being conducted across a geographically and clinically diverse spectrum of ICUs and hospitals in Canada (currently 36 sites), Australia (6 sites), New Zealand (10 sites), the USA (2 sites), Saudi Arabia (2 sites) and Israel (1 site). We commenced enrolment at the central study site, Sunnybrook Health Sciences Centre in Toronto, Canada, at the beginning of the vanguard pilot (October 2014) and then added each additional site in a staggered fashion after ethics approval, contract and site initiations were accomplished. We continue to welcome new sites into BALANCE and anticipate approximately 60--70 active sites by the time of trial completion.

Participants {#s2-3}
------------

Hospitalised patients will be considered for enrolment in this study if they meet all inclusion and no exclusion criteria.

### Inclusion criteria {#s2-3-1}

Patient is admitted to hospital at the time a blood culture result is reported as positive with a pathogenic bacterium.

### Exclusion criteria {#s2-3-2}

1.  Patient already enrolled in the trial.

2.  Patient has severe immune system compromise, as defined by: absolute neutrophil count \<0.5×10^9^/L or is receiving immunosuppressive treatment for solid organ or bone marrow or stem cell transplant.

3.  Patient has a prosthetic heart valve or synthetic endovascular graft (post major vessel repair with synthetic material; coronary artery stents are not an exclusion).

4.  Patient has a documented or strong suspicion of a syndrome with well-defined requirement for prolonged treatment: (1) infective endocarditis, (2) osteomyelitis/septic arthritis, (3) undrainable/undrained abscess and (4) unremovable/unremoved prosthetic-associated infection (eg, infected pacemaker, prosthetic joint infection, ventriculoperitoneal shunt infection). Central venous catheters, including tunnelled central intravenous catheter and urinary catheters are not excluded.

5.  Patient has a single positive blood culture with a common contaminant organism according to Clinical and Laboratory Standards Institute guidelines: coagulase-negative staphylococci, *Bacillus* spp, *Corynebacterium* spp, *Propionobacterium* spp, *Aerococcus* spp or *Micrococcus* spp.[@R34]

6.  Patient has a positive blood culture with *S. aureus* [@R35] *or S. lugdunensis.*

7.  Patient has a positive blood culture with rare bacterial pathogens requiring prolonged treatment (eg, *Mycobacteria* spp, *Nocardia* spp, *Actinomyces* spp, *Brucella* spp, *Burkholderia pseudomallei*).

8.  Patient has a positive blood culture with *Candida* spp or other fungal species.

Trial intervention {#s2-4}
------------------

We will randomise patients to receive a shorter duration of adequate antibiotic therapy (7 days) versus a longer duration (14 days) ([figure 1](#F1){ref-type="fig"}). Adequate antibiotic treatment will be defined as treatment with an antibiotic (or antibiotics) to which the local laboratory has reported the organism(s) responsible for the bloodstream infection as susceptible. The duration of adequate treatment will be determined as the cumulative number of days on which at least one dose of adequate treatment is delivered beyond the date of collection of the index blood culture specimen.[@R36] The selection of specific antimicrobial agent(s), doses and route of delivery will be at the discretion of the treating clinical team. The research team at each site will visit daily to ensure that antibiotics are stopped at the prespecified date (end of day 7 or 14).

![BALANCE RCT intervention flow diagram. BALANCE, Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness; *C. difficile*, *Clostridium difficile*; D/C, discontinue; ICU, intensive care unit; LOS, length of stay; RCT, randomised clinical trial.](bmjopen-2020-038300f01){#F1}

Randomisation and allocation concealment {#s2-5}
----------------------------------------

We will use web-based randomisation through RANDOMIZE.NET (<http://www.randomize.net/>), with variable block sizes, stratified by hospital site and by ICU versus non-ICU location. After the full susceptibility results become available, the site research coordinator along with site coinvestigators will determine the date for day 7 unblinding, taking into account the number of days that the patient has already received adequate antibiotics after the blood culture collection date. To avoid differentially influencing antibiotic choices and clinical decision-making, the randomisation assignment will not be communicated to any clinical staff or research personnel (research coordinator, study critical care or infectious diseases investigators)---until the end of day 7. At day 7, another email will be sent with the unblinded treatment assignment for the patient to the site research coordinator. If a patient is randomised to the short (day) treatment arm, the treating team will be informed to stop the antibiotics at the completion of 7 days of antibiotics appropriate for the causative pathogen; if the patient is randomised to the long (day 14) arm, the team will be instructed to continue the antibiotic until that date, including beyond hospital discharge if necessary.

Mechanistic substudies {#s2-6}
----------------------

### Biomarker substudy {#s2-6-1}

Blood samples will be drawn on the randomisation day and at days 7, 10 and 14 from the index blood culture collection to measure procalcitonin (PCT) levels along with other novel inflammatory and angiogenic biomarkers (soluble triggering receptor expressed on myeloid cells (s-TREM-1), tumor necrosis factor receptor (S-TNFR-1 and S-TNFR-2), interleukin 6, Chitinase-3-like protein (CHI3L-1), angiopoietin (Ang)-1, Ang-2, tyrosine kinase with immunoglobulin (sTIE1, sTIE2), soluble fms-like tyrosine kinase (sFlt-1), slit glycoprotein (Slt-2)/ Roundabout receptor (ROBO). The PCT levels will be batched and measured at the end of the study for the substudy assessing the association between PCT and clinical outcomes among patients receiving 7 vs 14 days of treatment. The results will not be made available to the treating team because this could unduly influence clinical practice and protocol adherence and is ethical because none of the participating sites are currently using PCT routinely. Following study completion, we will compare PCT area under the curve and day 7, 10 and 14 PCT levels among patients. We will also confirm whether 7 days of antibiotics is non-inferior to 14 days of antibiotics for bacteraemia, in subgroups with both normal and abnormal (\>0.25 μg/mL) PCT levels on day 7. We will conduct comparable analyses for the other inflammatory and angiogenic biomarkers.

### Microbiome substudy {#s2-6-2}

To assess the effect of shortening the duration of antibiotic administration on the human gut microbiome, we will collect rectal swabs from patients on the day of randomisation, and at days 7, 14 and 21 (or hospital discharge if earlier than day 21) from the start of appropriate antibiotic therapy. Flocked, sterile swabs will be inserted 2--3 cm past the anal verge, rotated three to four times, deposited into a room-temperature stable DNA/RNA preservative and stored at room temperature. No human sequence data will be obtained. Swabs will be transported for processing in batches, or at the end of the study, whichever is easier for the participating site. Samples will be processed for extraction of nucleic acid for 16S rRNA microbiome sequencing and shotgun metagenomics sequencing. Participants who decline sample collection for the substudies will still be included in the main clinical trial.

Protecting against sources of bias {#s2-7}
----------------------------------

### Selection bias {#s2-7-1}

Selection bias (such as bias-by-indication or survival bias) will be minimised through rigorous concealed randomisation procedures. Although placebo controls have been used in some RCTs of antibiotic treatment duration, such as studies examining treatment duration for cellulitis,[@R37] pyelonephritis[@R38] and community-acquired pneumonia,[@R40] they are not appropriate for bacteraemia treatment in acutely ill patients. It is not feasible to administer placebos for each of the many antimicrobials commonly used alone or in combination to treat the many aetiologies of bacteraemia.[@R44] Even if it were possible to generate this many placebos, BALANCE patients are susceptible to developing secondary sources of nosocomial infection, and our preparatory work revealed that clinicians demand knowledge of whether a patient is receiving antibiotics or not.

### Outcome misclassification bias {#s2-7-2}

We have selected an objective primary outcome measure and we will use central adjudication committees blinded to treatment allocation for other outcomes including relapse, and secondary infection/colonisation with antibiotic-resistant organisms.[@R45]

Withdrawal from study {#s2-8}
---------------------

If a patient is withdrawn from the study prematurely, a withdrawal form will be completed. Data will be collected under the informed consent up to the point of a consent withdrawal. Among patients who withdraw consent for continuation of the trial, we will seek their consent to ascertain vital status at ICU and hospital discharge and at 90 days from the date of bacteraemia diagnosis. Anticipated reasons for withdrawal include patient not meeting inclusion criteria or having relevant exclusion criteria prior to randomisation, consent withdrawn by patient or substitute decision-maker, patient's physician believes patient should be withdrawn from the study and inadvertent duplicate randomisation. Detailed rationales for withdrawal will be recorded.

Protocol adherence and protocol deviations {#s2-9}
------------------------------------------

We will define adherence to treatment duration protocol as receipt of 7±2 days of adequate antibiotics in the shorter duration arm, and 14±2 days in the longer duration arm; antibiotics stopped before or continued beyond these durations will be considered protocol deviations. We do not expect or aspire to achieve a 0% protocol deviation rate in this trial, given that some patients will develop persistent, recurrent or secondary infections for which antibiotics will need to be reinitiated or continued. It is appropriate for these patients to receive treatment as would occur outside of a trial. For example, in the multicentre *PneumoA* study of 8 vs 15 days of treatment for ventilator-associated pneumonia, protocol non-adherence was 18% in the 8-day treatment arm.[@R17] Non-adherence rates have been as high as 50% seen in some studies of PCT-guided treatment for infections in critically ill patients.[@R47] However, we will monitor protocol deviation rates overall and by hospital site during the trial, record rationales for the deviations, and strive to minimise unnecessary deviations.

Frequency and duration of follow-up {#s2-10}
-----------------------------------

Patients will be reviewed daily in hospital for the first 14 days postrandomisation, and again at hospital discharge with extensive data collection (see case report form at balance.ccctg.ca). The research coordinator will contact the patient (or substitute decision-maker as appropriate) on day 90 by telephone to determine their disposition and vital status. Other sources of evidence for 90-day vital status will include clinical documentation of healthcare visits/readmissions and testing after 90 days.

Primary outcome measure {#s2-11}
-----------------------

The primary outcome will be survival at 90 days from the date of bacteraemia, defined by the date of collection of the index positive blood culture. Although, most deaths from critical illness occur during hospital stay, lingering sequelae lead to a persistently elevated risk of death post-discharge. Therefore, we selected post-hospital 90-day mortality as a common vital status endpoint.[@R48]

Secondary outcome measures {#s2-12}
--------------------------

The secondary outcomes include: (1) hospital mortality, (2) ICU mortality, (3) relapse rates of bacteraemia with the same organism, (4) antibiotic allergy and adverse events, (5) rates of *C. difficile* infection in hospital, (6) rates of secondary nosocomial infection/colonisation with antimicrobial-resistant organisms in hospital, (7) ICU length of stay, (8) hospital length of stay, (9) mechanical ventilation duration and (10) antibiotic-free days.

Antimicrobial-resistant organisms will be defined based on a positive routine culture yielding a highly resistant microbial organism as defined by the Dutch nosocomial infection surveillance guidelines.[@R50] This broad definition includes methicillin-resistant *S. aureus*, vancomycin-resistant enterococci, extended-spectrum beta-lactamase producing Enterobacteriaceae, carbapenem-resistant Gram-negative bacilli and multidrug-resistant Gram-negative bacilli (with definition of multidrug resistance differing according to Enterobacteriaceae and non-Enterobacteriaceae species).[@R50] We will also conduct a sensitivity analysis limited to isolation of these organism(s) only from sterile site specimens (such as blood, cerebrospinal fluid, peritoneal fluid, synovial fluid, pleural fluid and tissue biopsies).

Antibiotic-free days will be calculated as the number of days alive and not on any antibiotics in the time period from collection of the index blood culture to 28 days after this date; patients who die prior to day 28 will be assigned 0 antibiotic-free days.

Statistical analysis {#s2-13}
--------------------

### Sample size {#s2-13-1}

The primary analysis will assess whether 7 days of treatment is associated with non-inferior 90-day survival in comparison to 14 days. We require 1686 patients per arm to establish a non-inferiority margin of −4% absolute decrement in survival ((baseline mortality 22%)[@R51] power 80%, alpha 0.025, one-sided equivalence test). We have inflated this to account for a maximum of 5% loss to follow-up and have incorporated early stopping rules to account for the three interim analyses (coefficient 1.017)[@R52] for a total sample size of 3626. Recent landmark trials in with similar baseline mortality rates have used −4% as a non-inferiority margin[@R54]; the US Food and Drug Administration has recommended a similar margin for analogous industry-sponsored trials.[@R56] The PneumA study of 8- vs 15-day treatment for ventilator associated pneumonia (VAP) used a non-inferiority margin of 10%,[@R17] as have other recent prominent infectious diseases non-inferiority trials,[@R20] but we believe lower non-inferiority margins are desirable, when feasible, for the outcome of survival.[@R56]

Loss to follow-up {#s2-14}
-----------------

We anticipate negligible loss of patients to follow-up. The Canadian Critical Care Trials Group (CCCTG) ([www.ccctg.ca](www.ccctg.ca)) has achieved virtually 100% follow-up to hospital discharge over all of its landmark RCTs.[@R58] Although we will be following survivors to ascertain 90-day mortality and relapse rates, we also expect close to 100% follow-up based on previous CCCTG experience and our own pilot RCT experience.[@R32] Nevertheless, we are accounting for up to 5% loss to follow-up in our sample size calculation.

Analysis of primary outcome {#s2-15}
---------------------------

The BALANCE trial will be conducted, analysed and reported according to CONSORT (Consolidated Standards of Reporting Trials) guidelines, including analysing patients in the groups to which they were assigned (intention to treat).[@R61] We will also include a per-protocol analysis. Inferences that 7-day treatment is non-inferior to 14-day treatment will be stronger if this finding is confirmed in both intention-to-treat and per-protocol analyses.[@R62] We will also perform a modified intention-to-treat (mITT) analysis, excluding patients who die before day 7 of treatment, given that these patients die prior to divergence in treatment assignment.[@R63] The primary analysis will examine whether 90-day survival is non-inferior in the 7- vs 14-day treatment group, as determined by whether the 95.7% CI excludes a 4% absolute decrement in survival.

Analysis of secondary outcomes {#s2-16}
------------------------------

Mortality rates at other time points will be calculated in a similar manner to 90-day mortality. We hypothesise that mortality rates will be non-inferior with 7 days of treatment. Continuous secondary outcomes, including lengths of stay in ICU and hospital, durations of ventilation and vasopressor use, and antibiotic-free days will be compared by the Wilcoxon test.

Subgroup analyses {#s2-17}
-----------------

The main subgroup analysis will be based on the underlying infectious syndrome causing bacteraemia (vascular catheter related, pneumonia, pyelonephritis, intra-abdominal, skin and soft tissue, other identified source or unknown source). We will also perform subgroup analyses based on ICU versus non-ICU enrolments, community versus hospital acquisition, Gram-positive vs Gram-negative infection, illness severity (Acute Physiology And Chronic Health Evaluation (APACHE II) score of ≥25 vs \<25) and vasopressor use on day of randomisation. We hypothesise that the non-inferiority of 7 vs 14 days of treatment will be consistent across these subgroups.

Frequency of analyses {#s2-18}
---------------------

Three interim analyses are planned for BALANCE at approximately 1/6 (600 patients), 1/3 (1200 patients) and 2/3 (2400 patients) of projected total enrolment; we will stop at the interim analysis for futility, inferiority or superiority using the O'Brien-Fleming spending function to generate adjusted CIs for the primary endpoint, splitting the type I error at 0.0000007, 0.000452, 0.013 and 0.043 with 99.99%, 99.95%, 98.68% and 95.70% two-sided CIs to give an overall type I error of 2.5%.[@R52] The data monitoring committee (DMC) will be guided by a graphical plot indicating mortality differences which would meet futility, inferiority or superiority thresholds ([figure 2](#F2){ref-type="fig"}). We will perform both frequentist-based and Bayesian-based analyses for endpoints at the study's termination. Subgroup analyses will not be performed for the interim analyses.

![Operationalising stopping guidelines for inferiority (dark grey shaded area), superiority (light grey shaded area) and futility (medium grey shaded area) with interim event rates at the first interim analysis (n=600). Similar figures are available to the data monitoring committee for subsequent interim analyses.](bmjopen-2020-038300f02){#F2}

Secondary Bayesian analysis {#s2-19}
---------------------------

Usual frequentist-based statistical analysis calculates the probability of obtaining data as extreme or more extreme than the observed data assuming the null hypothesis is true. Interpretations of clinical trials based on frequentist statistics using p-values and 95% CIs can be challenging for clinicians for several reasons. First, frequentist-based analyses usually consider each analysis in isolation, without an easy mechanism for quantitatively incorporating prior information and without a true measure of the probability of clinical benefit. Quantitative interpretation of new information from clinical trials can be especially challenging when either prior evidence or perception does not align with new evidence.[@R64] The interpretation of results of trials using a non-inferiority perspective can be additionally challenging, requiring interpretation of findings that may indicate non-inferiority, inferiority, superiority, equivalence or an inconclusive estimate of effect.[@R67] Bayesian methods provide an alternative to null hypothesis statistical testing that allow quantification of evidence in favour of the null hypothesis, sequential testing and comparison of strength of evidence across different studies.[@R68] In addition to our primary frequentist-based analysis of the primary 90-day mortality outcome, and secondary in-hospital and in-ICU mortality outcomes, we will additionally perform companion Bayesian analyses of each. This will be particularly informative should the study be either stopped for futility (a high likelihood of being unable to determine superiority, inferiority or non-inferiority at planned or feasible samples sizes) to directly estimate the *probability* of treatment benefits. We will combine the data from BALANCE with a non-informative prior to deriving the posterior distribution based on which we will report the 95% credible intervals together with the probabilities of the difference in mortality between the two groups falling into the superiority, non-inferiority and inferiority regions.

Steering committee {#s2-20}
------------------

The BALANCE steering committee is responsible for the development and oversight of the BALANCE RCT procedures, rigorous and ethical trial conduct, funding applications, advising the principal applicants on responses to questions from ethics boards, the DMC or other stakeholders, and eventual interpretation and compilation of study results into reports, scholarly manuscripts and knowledge translation (KT) and exchange activities. With BALANCE expansion to additional countries, additional steering committee member(s) will be added from each country with two or more enrolling sites and/or has obtained regional grant funding to support the trial.

Data monitoring ommittee {#s2-21}
------------------------

The BALANCE DMC has multidisciplinary expertise in infectious diseases, critical care, RCT design and conduct, clinical epidemiology, biostatistics, interim analyses and early stopping rules. The BALANCE DMC charter ([online supplementary file](#SP1){ref-type="supplementary-material"}) is based on the Data Monitoring Committees: Lessons, Ethics, Statistics (DAMOCLES) Study Group charter, and draws heavily from the charter and experience of prior landmark CCCTG studies.[@R58] At each interim analysis, the BALANCE principal investigators will provide the DMC with information on group characteristics, recruitment rates, adherence to treatment duration protocols, data completeness and accuracy, serious adverse events (SAEs), outcome event rates and co-enrolment prevalence. Data will be presented in both one-group or two-group tables in a manner that will prevent unmasking of group allocation to the research team. The DMC will be able to request an independent (not involved in the BALANCE trial) methods centre statistician to provide the unmasked group allocation, according to the BALANCE charter ([online supplementary file](#SP1){ref-type="supplementary-material"}), should that be deemed necessary by the DMC to interpret the interim analysis.
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Patient and public involvement {#s2-22}
------------------------------

The CCCTG includes a Patient and Family Partnership Committee (<https://cccrpf.ca/>) that has been engaged throughout BALANCE development and conduct.

Ethics and dissemination {#s3}
========================

Ethics approval {#s3-1}
---------------

Ethics approval has been obtained from the research ethics board of each participating site, along with central mechanisms in the Canadian provinces of Ontario and Quebec, the Australian states of New South Wales and Victoria and New Zealand ([online supplementary file 2](#SP2){ref-type="supplementary-material"}).

10.1136/bmjopen-2020-038300.supp2

Consent {#s3-2}
-------

The research coordinator/site primary investigator will approach eligible patients (or their substitute decision-makers) as soon as their blood cultures are positive to obtain informed consent. Enrolment can be delayed at maximum to the day 7 of adequate antibiotic treatment. Critically ill patients are frequently unable to provide initial consent due to altered level of consciousness or comprehension, and thus the CCCTG has standard operating procedures to seek assistance from substitute decision-makers on behalf of patients. This process has been found feasible and acceptable to patients, decision-makers and research ethics boards across Canada.[@R73] We will use this enhanced approach to consent, employing 13 previously described strategies distributed over three phases: preparation for the consent encounter, the consent encounter and follow-up to the consent encounter.[@R77]

Expected adverse events {#s3-3}
-----------------------

Short-course (7 days) treatment duration could theoretically increase the risk of clinical treatment failure or relapse of the bloodstream infection or underlying focus of infection. Long-course (14 days) treatment on the other hand may increase the chance of resistance to antibiotics; occurrence of new antibiotic-resistant infections; *C. difficile* infection; and adverse events like allergy, anaphylaxis, antibiotic-related kidney injury, antibiotic-related hepatitis and other antibiotic-related organ toxicity. Our systematic review suggests that clinical cure and survival are similar among patients with bacteraemia receiving shorter and longer treatment, but these represent underpowered, post hoc subgroup analyses pooled from small trials.[@R33] Any observational study assessing the impact of duration of treatment on patient outcomes would be limited by survivor bias (patients must survive long enough to be classified as receiving longer treatment) and indication bias (clinicians select sicker patients to receive longer duration treatment). Hence, patients and clinicians require a sufficiently powered RCT dedicated to answering the question of whether shorter treatments are effective for patients with bloodstream infection.

Morbidity and mortality are expected among patients with bloodstream infections. Accordingly, mortality at 90 days, in ICU and in hospital are trial outcomes, as are episodes of *C. difficile* colitis, and antibiotic-related allergy and adverse effects. Outcomes will be reported as such, rather than as SAEs, serious unexpected adverse reactions or suspected unexpected serious adverse reactions. These outcomes will be reported to the DMC at all interim analyses. We will closely monitor patient safety in the trial by recording the antimicrobial-related adverse events and serious unexpected adverse drug reactions, additionally interpreted by the steering committee and reported to the DMC at each interim analysis.

Knowledge dissemination {#s3-4}
-----------------------

A major mandate of the CCCTG is translating knowledge into practice and advancing the science of KT in critically ill hospitalised patients. The study has also been endorsed by the Association of Medical Microbiology and Infectious Diseases Canada Clinical Research Network (AMMI Canada CRN), the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS-CTG) and the Australasian Society for Infectious Diseases Clinical Research Network (ASID-CRN). The involvement of the knowledge users and leaders in these organisations will lead to rapid national and international knowledge dissemination.

Discussion {#s4}
==========

Rationale for why the BALANCE trial is urgently needed {#s4-1}
------------------------------------------------------

The WHO, US Centers for Disease Control and Prevention, AMMI Canada and Health Canada have all declared antimicrobial resistance a global threat to health,[@R1] based on rapidly increasing resistance rates and declining new drug development.[@R5] The highest rates of antimicrobial resistance occur in hospitals, and ICUs in particular, and it is crucial that we develop data-informed mechanisms to decrease antimicrobial use and selection pressure. The vulnerability of acutely ill patients, the complexity of their treatments and the frequent uncertainty of their infectious syndromic diagnoses are all barriers to reducing antibiotic exposure in the ICU. It is very difficult to avoid initial broad-spectrum antibiotic treatment when acutely ill patients present with or develop definite or suspected infection. Multiple studies have demonstrated that early administration of effective antibiotics in the initial empiric window of antibiotic treatment is the strongest predictor of a favourable outcome in these patients. If empiric selections do not match the susceptibility profile of the isolated pathogen, the patient may be nearly twice as likely to die.[@R78] Given that prevailing resistance rates are already high, broad-spectrum initial treatments are appropriate for many acutely ill patients. In contrast, it is much more feasible to reduce antibiotic use at the end of treatment courses, given that most patients may be treated longer than necessary, and excessive antibiotic durations are a top contributor to inappropriate antibiotic in all healthcare sectors.[@R7] Shorter duration treatments have been demonstrated to be non-inferior to longer duration treatments for a range of infections.[@R11] If BALANCE confirms this finding among patients with bacteraemia, it could result in effective but shorter prescribing practices for these patients. Shortening treatment durations should also reduce other adverse events, including *C. difficile* infections, and generate an estimated annual direct antimicrobial cost savings of \$C678--\$C798 million across North America and C\$1.4--1.6 billion across Europe.[@R80]

Rationale for studying fixed duration therapy rather than individualised durations of treatment {#s4-2}
-----------------------------------------------------------------------------------------------

Ideally antibiotic treatment duration should be individualised, and each patient should receive exactly as much antibiotic treatment as needed until their infection is cured, and not longer.[@R24] However, an RCT based on a clinical stopping rule may not be feasible in acutely ill patients, since there are currently no proven accurate measures of cure versus persistent infection. The challenge in diagnosing and monitoring infection in ICU has sparked studies of novel biomarkers to guide antibiotic treatment duration.[@R43] One biomarker, PCT, has been used successfully to reduce average treatment durations in sepsis.[@R43] However, follow-up meta-analyses have indicated that the bacteraemic subgroups in PCT trials have tended to receive prolonged treatment durations,[@R82] perhaps because of high non-adherence rates to algorithm-guided treatment.[@R47] Therefore, we have designed a randomised trial of fixed shorter versus longer duration antibiotic therapy, guided by our preparatory studies, as the most easily transferable result to immediately inform clinical practice. This approach has been successful in more than two dozen randomised controlled trials of infectious diseases that are potentially complicated by bacteraemia.[@R19] However, we appreciate the future promise of biomarkers to add nuance to individualised treatment decisions, and so in a nested substudy, we will measure PCT and other novel biomarker levels and trajectory in both treatment arms to see if they could provide incremental value.[@R61]

Trial status {#s5}
============

The BALANCE pilot RCT was launched in October 2014 at the central study site, Sunnybrook Health Sciences Centre, expanded to include a total of 10 CCCTG sites across Canada and served as a successful vanguard for this BALANCE main RCT. An additional 26 Canadian sites have joined BALANCE, for a total of 36 Canadian sites in six provinces. A parallel BALANCE pilot RCT on medical and surgical wards was launched in October 2016 at a subset of six BALANCE sites, which confirmed the feasibility of recruitment and protocol adherence on non-ICU wards[@R33] and enabled hospital-wide expansion; approximately half of sites have now opted for hospital-wide enrolments. We have expanded BALANCE internationally to include sites in Australia (6), New Zealand (10), Saudi Arabia (2), Israel (1) and the USA (2). Therefore, there are currently 57 sites enrolling patients into BALANCE, and with continued expansion we anticipate approximately 70 sites prior to study completion (anticipated for 2022--2023). The BALANCE DMC conducted the first interim analysis (n=600) on 30 September 2019 and recommended continuing enrolment. As of 13 February 2020, a total of 1447 patients have been recruited into BALANCE, and data from the first 1200 patients are being analysed for the DMC review of the second interim analysis.
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